Varicella zoster virus vaccines: an update

References

• Arvin AM. Varicella-zoster virus. Clin Microbiol Rev. 1996;9(3):361–381. doi:10.1128/CMR.9.3.3618809466
   PubMed Web of Science ®Google Scholar
• Heininger U, Seward JF. Varicella. Lancet. 2006;368(9544):1365–1376. doi:10.1016/S0140-6736(06)69561-517046469
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed. Hamborsky J, Kroger A, Wolfe S, editors. 13th ed. Supplement. Washington (DC): Public Health Foundation; 2017.
   Google Scholar
• Malavige GN, Jones L, Kamaladasa SD, et al. Viral load, clinical disease severity and cellular immune responses in primary varicella zoster virus infection in Sri Lanka. Zimmer J, ed. PLoS One. 2008;3(11):e3789. doi:10.1371/journal.pone.000378919023425
   PubMed Web of Science ®Google Scholar
• Gershon AA, Breuer J, Cohen JI, et al. Varicella zoster virus infection. Nat Rev Dis Prim. 2015;1:15016. doi:10.1038/nrdp.2015.1627188665
   PubMed Web of Science ®Google Scholar
• Varicella and herpes zoster vaccines: WHO position paper, June 2014. Wkly Epidemiol Rec. 2014;(25):265–288. Available from: https://www.who.int/immunization/policy/position_papers/varicella/en/. Accessed March 1, 2019.24983077
   PubMedGoogle Scholar
• Spoulou V, Alain S, Gabutti G, et al. Implementing universal varicella vaccination in Europe. Pediatr Infect Dis J. 2019;38(2):181–188. doi:10.1097/INF.000000000000218530408002
   PubMed Web of Science ®Google Scholar
• Warren-Gash C, Forbes H, Breuer J. Varicella and herpes zoster vaccine development: lessons learned. Expert Rev Vaccines. 2017;16(12):1191–1201. doi:10.1080/14760584.2017.139484329047317
   PubMed Web of Science ®Google Scholar
• Seward JF, Marin M. Varicella disease burden and varicella vaccines. WHO Sage Meet. 2014 Available from: http://www.who.int/immunization/sage/meetings/2014/april/2_SAGE_April_VZV_Seward_Varicella.pdf. Accessed March 3, 2019.
   Google Scholar
• Meyer PA, Seward JF, Jumaan AO, Wharton M. Varicella mortality: trends before vaccine licensure in the United States, 1970–1994. J Infect Dis. 2000;182(2):383–390. doi:10.1086/jid.2000.182.issue-210915066
   PubMed Web of Science ®Google Scholar
• Riera-Montes M, Bollaerts K, Heininger U, et al. Estimation of the burden of varicella in Europe before the introduction of universal childhood immunization. BMC Infect Dis. 2017;17(1):353. doi:10.1186/s12879-017-2757-228521810
   PubMed Web of Science ®Google Scholar
• Advisory Committee on Immunization Practices Centers for Disease Control and Prevention (CDC). Guiding principles for development of ACIP recommendations for vaccination during pregnancy and breastfeeding. MMWR Morb Mortal Wkly Rep. 2008;57(21):580.18509303
   PubMedGoogle Scholar
• Streng A, Grote V, Carr D, Hagemann C, Liese JG. Varicella routine vaccination and the effects on varicella epidemiology – results from the Bavarian Varicella Surveillance Project (BaVariPro), 2006-2011. BMC Infect Dis. 2013;13(1):303. doi:10.1186/1471-2334-13-30323815523
   PubMed Web of Science ®Google Scholar
• Steain M, Sutherland JP, Rodriguez M, et al. Analysis of T cell responses during active varicella-zoster virus reactivation in human ganglia. J Virol. 2014;88(5):2704–2716. doi:10.1128/JVI.03445-1324352459
   PubMed Web of Science ®Google Scholar
• Brosio F, Masetti G, Matteo G, Stefanati A, Gabutti G. A novel nonlive, adjuvanted herpes zoster subunit vaccine: a report on the emerging clinical data and safety profile. Infect Drug Resist. 2018;11:1401–1411. doi:10.2147/IDR.S14830330233219
   PubMed Web of Science ®Google Scholar
• Ohfuji S, Ito K, Inoue M, et al. Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study. BMC Infect Dis. 2019;19(1):95. doi:10.1186/s12879-019-3719-730691396
   PubMed Web of Science ®Google Scholar
• Bricout H, Haugh M, Olatunde O, Gil Prieto R. Herpes zoster-associated mortality in Europe: a systematic review. BMC Public Health. 2015;15(1):466. doi:10.1186/s12889-015-1753-y25940080
   PubMed Web of Science ®Google Scholar
• Vink P, Delgado Mingorance I, Maximiano Alonso C, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial. Cancer. 2019. doi:10.1002/cncr.31909
   Web of Science ®Google Scholar
• Johnson RW, Alvarez-Pasquin M-J, Bijl M, et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. Ther Adv Vaccines. 2015;3(4):109–120. doi:10.1177/205101361559915126478818
   PubMedGoogle Scholar
• Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833–e004833. doi:10.1136/bmjopen-2014-004833
   PubMed Web of Science ®Google Scholar
• Gabutti G, Franco E, Bonanni P, et al. Reducing the burden of Herpes Zoster in Italy. Hum Vaccin Immunother. 2015;11(1):101. doi:10.4161/hv.3436325483522
   PubMed Web of Science ®Google Scholar
• Marin M, Yawn BP, Hales CM, et al. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status. Hum Vaccin Immunother. 2015;11(5):1157–1164. doi:10.1080/21645515.2015.101668125806911
   PubMed Web of Science ®Google Scholar
• Rommelaere M, Maréchal C, Yombi J-C, Goffin E, Kanaan N. Disseminated varicella zoster virus infection in adult renal transplant recipients: outcome and risk factors. Transplant Proc. 2012;44(9):2814–2817. doi:10.1016/j.transproceed.2012.09.09023146530
   PubMed Web of Science ®Google Scholar
• Zorzoli E, Pica F, Masetti G, Franco E, Volpi A, Gabutti G. Herpes zoster in frail elderly patients: prevalence, impact, management, and preventive strategies. Aging Clin Exp Res. 2018;30(7):693–702. doi:10.1007/s40520-018-0956-329721782
   PubMed Web of Science ®Google Scholar
• Langan SM, Smeeth L, Margolis DJ, Thomas SL. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older us population: a cohort study. Harbarth S, ed. PLoS Med. 2013;10(4):e1001420. doi:10.1371/journal.pmed.100142023585738
   PubMed Web of Science ®Google Scholar
• Gabutti G, Valente N, Kuhdari P, Lupi S, Stefanati A. Prevention of herpes zoster and its complications: from the clinic to the real-life experience with the vaccine. J Med Microbiol. 2016;65(12):1363–1369. doi:10.1099/jmm.0.00038627902409
   PubMed Web of Science ®Google Scholar
• Panatto D, Bragazzi NL, Rizzitelli E, et al. Evaluation of the economic burden of Herpes Zoster (HZ) infection. Hum Vaccin Immunother. 2015;11(1):245–262. doi:10.4161/hv.3616025483704
   PubMed Web of Science ®Google Scholar
• Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet (London, England). 1974;2(7892):1288–1290. doi:10.1016/S0140-6736(74)90144-5
   PubMed Web of Science ®Google Scholar
• WHO. Observed rate of vaccine reactions - Varicella zoster virus vaccine. Inf Sheet WHO. 2012;4 Available from: https://www.who.int/vaccine_safety/initiative/tools/Varicella_Zoster_Vaccine_rates_information_sheet.pdf. Accessed March 2, 2019.
   Google Scholar
• Prymula R, Bergsaker MR, Esposito S, et al. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. Lancet. 2014;383(9925):1313–1324. doi:10.1016/S0140-6736(13)61612-824485548
   PubMed Web of Science ®Google Scholar
• Bonanni P, Gershon A, Gershon M, et al. Primary versus secondary failure after varicella vaccination: implications for interval between 2 doses. Pediatr Infect Dis J. 2013;32(7):e305–e13. doi:10.1097/INF.0b013e31828b7def23838789
   PubMed Web of Science ®Google Scholar
• Marin M, Marti M, Kambhampati A, Jeram SM, Seward JF. Global varicella vaccine effectiveness: a meta-analysis. Pediatrics. 2016;137(3):e20153741. doi:10.1542/peds.2015-374126908671
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). National, state, and urban area vaccination coverage among children aged. 19-35 months–united States, 2005. MMWR Morb Mortal Wkly Rep. 2006;55(36):988–993.16971887
   PubMedGoogle Scholar
• Bialek SR, Perella D, Zhang J, et al. Impact of a routine two-dose varicella vaccination program on varicella epidemiology. Pediatrics. 2013;132(5):e1134–40. doi:10.1542/peds.2013-086324101763
   PubMed Web of Science ®Google Scholar
• Vázquez M, LaRussa PS, Gershon AA, et al. Effectiveness Over Time of Varicella Vaccine. JAMA. 2004;291(7):851. doi:10.1001/jama.291.7.85114970064
   PubMed Web of Science ®Google Scholar
• Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J. 2004;23(2):132–137. doi:10.1097/01.inf.0000109287.97518.6714872179
   PubMed Web of Science ®Google Scholar
• Cameron JC, Allan G, Johnston F, Finn A, Heath PT, Booy R. Severe complications of chickenpox in hospitalised children in the UK and Ireland. Arch Dis Child. 2007;92(12):1062–1066. doi:10.1136/adc.2007.12323217991685
   PubMed Web of Science ®Google Scholar
• Galea SA, Sweet A, Beninger P, et al. The Safety Profile of Varicella Vaccine: A 10‐Year Review. J Infect Dis. 2008;197(s2):S165–S169.18419392
   PubMed Web of Science ®Google Scholar
• Kanra G, Ceyhan M, Özmert E. Safety and immunogenicity of live attenuated varicella vaccine in 9-month-old children. Pediatr Int. 2000;42(6):674–677.11192526
   PubMed Web of Science ®Google Scholar
• Leung JH, Hirai HW, Tsoi KK. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials. Expert Rev Vaccines. 2015;14(8):1149–1157. doi:10.1586/14760584.2015.105757226081133
   PubMed Web of Science ®Google Scholar
• Ma S-J, Li X, Xiong Y-Q, Yao A-L, Chen Q. Combination measles-mumps-rubella-varicella vaccine in healthy children: a systematic review and meta-analysis of immunogenicity and safety. Medicine (Baltimore). 2015;94(44):e1721. doi:10.1097/MD.000000000000087426554769
   PubMed Web of Science ®Google Scholar
• Jacobsen SJ, Ackerson BK, Sy LS, et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine. 2009;27(34):4656–4661. doi:10.1016/j.vaccine.2009.05.05619520201
   PubMed Web of Science ®Google Scholar
• Klein NP, Fireman B, Yih WK, et al. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010;126(1):e1–e8. doi:10.1542/peds.2010-066520587679
   PubMed Web of Science ®Google Scholar
• Macartney K, Gidding HF, Trinh L, et al. Evaluation of combination measles-mumps-rubella-varicella vaccine introduction in Australia. JAMA Pediatr. 2017;171(10):992. doi:10.1001/jamapediatrics.2017.196528806450
   PubMed Web of Science ®Google Scholar
• Gabutti G, Kuhdari P, Ferioli S, Trucchi C. Hospital admissions for seizure in Italy: a decennial retrospective analysis with a special focus on the burden in the pediatric age. Neurol Sci. 2015;36(9):1667–1673. doi:10.1007/s10072-015-2230-125926071
   PubMed Web of Science ®Google Scholar
• Knuf M, Faber J, Barth I, Habermehl P. A combination vaccine against measles, mumps, rubella and varicella. Drugs Today (Barc). 2008;44(4):279–292. doi:10.1358/dot.2008.44.4.121075518536786
   PubMed Web of Science ®Google Scholar
• Hope-Simpson R. The nature of Herpes Zoster: a long-term study and a new Hypothesis. Proc R Soc Med. 1965;58(1):9–20.14267505
   PubMedGoogle Scholar
• Oxman MN. Zoster vaccine: current status and future prospects. Clin Infect Dis. 2010;51(2):197–213. doi:10.1086/65297620550454
   PubMed Web of Science ®Google Scholar
• Dooling KL, Guo A, Patel M, et al. Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67(3):103–108. doi:10.15585/mmwr.mm6731e229370152
   PubMed Web of Science ®Google Scholar
• Simberkoff MS, Arbeit RD, Johnson GR, et al. Safety of herpes zoster vaccine in the shingles prevention study. Ann Intern Med. 2010;152(9):545. doi:10.7326/0003-4819-152-9-201005040-0000420439572
   PubMed Web of Science ®Google Scholar
• Zussman J, Young L. Zoster vaccine live for the prevention of shingles in the elderly patient. Clin Interv Aging. 2008;3(2):241–250.18686747
   PubMed Web of Science ®Google Scholar
• Rafael Harpaz MD, Ortega-Sanchez IR PhD, Jane F, Seward M Available from: Prevention of Herpes Zoster Recommendations of the Advisory Committee on Immunization Practices (ACIP). https://www.cdc.gov/mmwr/preview/mmwrhtml/rr57e0515a1.htm. Accessed 3 21, 2019.
   Google Scholar
• Schmader KE, Johnson GR, Saddier P, et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. J Am Geriatr Soc. 2010;58(9):1634–1641. doi:10.1111/j.1532-5415.2010.03021.x20863322
   PubMed Web of Science ®Google Scholar
• Oxman MN, Levin MJ, Shingles Prevention Study Group. Vaccination against Herpes Zoster and postherpetic neuralgia. J Infect Dis. 2008;197(s2):S228–S236. doi:10.1086/52215918419402
   PubMed Web of Science ®Google Scholar
• Lu P, Euler GL, Jumaan AO, Harpaz R. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors. Vaccine. 2009;27(6):882–887. doi:10.1016/j.vaccine.2008.11.07719071175
   PubMed Web of Science ®Google Scholar
• Schmader KE, Levin MJ, Gnann JW, et al. Efficacy, safety, and tolerability of Herpes Zoster vaccine in persons aged 50–59 Years. Clin Infect Dis. 2012;54(7):922–928. doi:10.1093/cid/cir97022291101
   PubMed Web of Science ®Google Scholar
• Willis ED, Woodward M, Brown E, et al. Herpes zoster vaccine live: A 10 year review of post-marketing safety experience. Vaccine. 2017;35(52):7231–7239. doi:10.1016/j.vaccine.2017.11.01329174682
   PubMed Web of Science ®Google Scholar
• Gabutti G, Valente N, Sulcaj N, Stefanati A. Evaluation of efficacy and effectiveness of live attenuated zoster vaccine. J Prev Med Hyg. 2014;55(4):130–136.26137786
   PubMedGoogle Scholar
• Miller ER, Lewis P, Shimabukuro TT, et al. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006–2015. Hum Vaccin Immunother. 2018;14(8):1963–1969. doi:10.1080/21645515.2018.145659829580194
   PubMed Web of Science ®Google Scholar
• Gagliardi AM, Gomes Silva BN, Torloni MR, Soares BG. Vaccines for preventing herpes zoster in older adults In: Gagliardi AM, editor. Cochrane Database of Systematic Reviews. Vol. 10 Chichester, UK: John Wiley & Sons, Ltd; 2012:CD008858.23076951
   PubMedGoogle Scholar
• European Medicines Agency (EMA). SmPC Zostavax Available from: https://www.ema.europa.eu/en/documents/product-information/zostavax-epar-product-information_en.pdf. Accessed 41, 2019.
   Google Scholar
• Levin MJ, Schmader KE, Pang L, et al. Cellular and humoral responses to a second dose of Herpes Zoster vaccine administered 10 years after the first dose among older adults. J Infect Dis. 2016;213(1):14–22. doi:10.1093/infdis/jiv48026452397
   PubMed Web of Science ®Google Scholar
• Reddy KP. Herpes Zoster vaccine: time for a boost? J Gen Intern Med. 2017;32(2):145–147. doi:10.1007/s11606-016-3885-x27730484
   PubMed Web of Science ®Google Scholar
• Walker JL, Andrews NJ, Amirthalingam G, Forbes H, Langan SM, Thomas SL. Effectiveness of herpes zoster vaccination in an older United Kingdom population. Vaccine. 2018;36(17):2371–2377. doi:10.1016/j.vaccine.2018.02.02129555217
   PubMed Web of Science ®Google Scholar
• Yun H, Xie F, Baddley JW, Winthrop K, Saag KG, Curtis JR. Longterm effectiveness of Herpes Zoster vaccine among patients with autoimmune and inflammatory diseases. J Rheumatol. 2017;44(7):1083–1087. doi:10.3899/jrheum.16068528298565
   PubMed Web of Science ®Google Scholar
• Tseng HF, Luo Y, Shi J, et al. Effectiveness of Herpes Zoster vaccine in patients 60 years and older with end-stage renal disease. Clin Infect Dis. 2015;62(4):civ930. doi:10.1093/cid/civ930
   Web of Science ®Google Scholar
• Izurieta HS, Wernecke M, Kelman J, et al. Effectiveness and duration of protection provided by the live-attenuated Herpes Zoster vaccine in the medicare population ages 65 years and older. Clin Infect Dis. 2017;64(6):785–793. doi:10.1093/cid/ciw85428362955
   PubMed Web of Science ®Google Scholar
• Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of Herpes Zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308(1):43–49. doi:10.1001/jama.2012.730422760290
   PubMed Web of Science ®Google Scholar
• Amirthalingam G, Andrews N, Keel P, et al. Evaluation of the effect of the herpes zoster vaccination programme 3 years after its introduction in England: a population-based study. Lancet Public Heal. 2018;3(2):e82–e90. doi:10.1016/S2468-2667(17)30234-7
   PubMed Web of Science ®Google Scholar
• Kawai K, Preaud E, Baron-Papillon F, Largeron N, Acosta CJ. Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review. Vaccine. 2014;32(15):1645–1653. doi:10.1016/j.vaccine.2014.01.05824534737
   PubMed Web of Science ®Google Scholar
• European Commission, Commission implementing decision of 21.3.2018, granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for “Shingrix - herpes zoster vaccine (recombinant, adjuvanted)”, a medicinal product for human use. Available from: https://ec.europa.eu/health/documents/community-register/2018/20180321140171/dec_140171_en.pdf. Accessed 48, 2019.
   Google Scholar
• Cunningham AL, Lal H, Kovac M, et al. Efficacy of the Herpes Zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–1032. doi:10.1056/NEJMoa160380027626517
   PubMed Web of Science ®Google Scholar
• Cunningham AL, Heineman TC, Lal H, et al. Immune responses to a recombinant glycoprotein E Herpes Zoster vaccine in adults aged 50 years or older. J Infect Dis. 2018;217(11):1750–1760. doi:10.1093/infdis/jiy09529529222
   PubMed Web of Science ®Google Scholar
• Dendouga N, Fochesato M, Lockman L, Mossman S, Giannini SL. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine. 2012;30(20):3126–3135. doi:10.1016/j.vaccine.2012.01.08822326899
   PubMed Web of Science ®Google Scholar
• Chlibek R, Bayas JM, Collins H, et al. Safety and Immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against Herpes Zoster in adults ≥50 years of age. J Infect Dis. 2013;208(12):1953–1961. doi:10.1093/infdis/jit36523904292
   PubMed Web of Science ®Google Scholar
• Chlibek R, Smetana J, Pauksens K, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: A phase II, randomized, controlled study. Vaccine. 2014;32(15):1745–1753. doi:10.1016/j.vaccine.2014.01.01924508036
   PubMed Web of Science ®Google Scholar
• Chlibek R, Pauksens K, Rombo L, et al. Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine. 2016;34(6):863–868. doi:10.1016/j.vaccine.2015.09.07326432913
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Volpe S, Catteau G, et al. Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults. Hum Vaccin Immunother. 2018;14(6):1370–1377. doi:10.1080/21645515.2018.144216229461919
   PubMed Web of Science ®Google Scholar
• Grupping K, Campora L, Douha M, et al. Immunogenicity and safety of the HZ/su adjuvanted herpes zoster subunit vaccine in adults previously vaccinated with a live attenuated Herpes Zoster vaccine. J Infect Dis. 2017;216(11):1343–1351. doi:10.1093/infdis/jix48229029122
   PubMed Web of Science ®Google Scholar
• Vink P, Shiramoto M, Ogawa M, et al. Safety and immunogenicity of a Herpes Zoster subunit vaccine in Japanese population aged ≥50 years when administered subcutaneously vs. intramuscularly. Hum Vaccin Immunother. 2017;13(3):574. doi:10.1080/21645515.2016.123278727936344
   PubMed Web of Science ®Google Scholar
• Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted Herpes Zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–2096. doi:10.1056/NEJMoa150118425916341
   PubMed Web of Science ®Google Scholar
• Kovac M, Lal H, Cunningham AL, et al. Complications of herpes zoster in immunocompetent older adults: incidence in vaccine and placebo groups in two large phase 3 trials. Vaccine. 2018;36(12):1537–1541. doi:10.1016/j.vaccine.2018.02.02929463421
   PubMed Web of Science ®Google Scholar
• Stadtmauer EA, Sullivan KM, Marty FM, et al. A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood. 2014;124(19):2921–2929. doi:10.1182/blood-2014-04-57304825237196
   PubMed Web of Science ®Google Scholar
• Berkowitz EM, Moyle G, Stellbrink H-J, et al. Safety and Immunogenicity of an adjuvanted Herpes Zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2015;211(8):1279–1287. doi:10.1093/infdis/jiu60625371534
   PubMed Web of Science ®Google Scholar
• Winston DJ, Mullane KM, Cornely OA, et al. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10135):2116–2127. doi:10.1016/S0140-6736(18)30631-729856344
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA briefing document: Shingrix (Zoster Vaccine Recombinant, Adjuvanted). Presented at the Vaccines and Related Biological Products Advisory Committee Meeting 2017; Silver Spring, MD.
   Google Scholar
• Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2015;33(36):4398–4405. doi:10.1016/j.vaccine.2015.07.03526209838
   PubMed Web of Science ®Google Scholar
• Hesse EM, Shimabukuro TT, Su JR, et al. Postlicensure safety surveillance of recombinant Zoster vaccine (Shingrix) - United States, October 2017-June 2018. MMWR Morb Mortal Wkly Rep. 2019;68(4):91–94. doi:10.15585/mmwr.mm6804a430703077
   PubMed Web of Science ®Google Scholar
• Le P, Rothberg MB. Determining the optimal vaccination schedule for Herpes Zoster: a cost-effectiveness analysis. J Gen Intern Med. 2017;32(2):159–167. doi:10.1007/s11606-016-3844-627743284
   PubMed Web of Science ®Google Scholar
• de Boer PT, van Lier A, de Melker H, et al. Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines. BMC Med. 2018;16(1):228. doi:10.1186/s12916-018-1213-530518427
   PubMed Web of Science ®Google Scholar
• Van Oorschot D, Anastassopoulou A, Poulsen Nautrup B, et al. Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old. Hum Vaccin Immunother. 2019;15(1):34–44. doi:10.1080/21645515.2018.150964530130448
   PubMed Web of Science ®Google Scholar
• You JHS, Ming W, Tsang OT, Chan PK. Optimal gender-specific age for cost-effective vaccination with adjuvanted herpes zoster subunit vaccine in Chinese adults. van Wouwe JP, ed. PLoS One. 2019;14(1):e0210005. doi:10.1371/journal.pone.021000530608953
   PubMed Web of Science ®Google Scholar
• Curran D, Patterson BJ, Van Oorschot D, et al. Cost-effectiveness of an adjuvanted recombinant Zoster vaccine in older adults in the United States who have been previously vaccinated with Zoster vaccine live. Hum Vaccin Immunother. 2019;15(4):765–771.30625011
   PubMed Web of Science ®Google Scholar
• Kroger AT, Vázquez M. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Available from: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html. Published 2011 Accessed 315, 2019.
   Google Scholar
• Schwarz TF, Aggarwal N, Moeckesch B, et al. Immunogenicity and safety of an adjuvanted Herpes Zoster subunit vaccine coadministered with seasonal influenza vaccine in adults aged 50 years or older. J Infect Dis. 2017;216(11):1352–1361. doi:10.1093/infdis/jix48129029224
   PubMed Web of Science ®Google Scholar
• WHO. Requirements for varicella vaccine (live), WHO Technical Report Series, No. 848. Available from: http://www.who.int/biologicals/publications/trs/areas/vaccines/varicella/WHO_TRS_848_A1.pdf. Published 1994 Accessed 218, 2019.
   Google Scholar
• Oh SH, Choi EH, Shin SH, et al. Varicella and varicella vaccination in South Korea. Clin Vaccine Immunol. 2014;21(5):762–768. doi:10.1128/CVI.00645-1324671555
   PubMed Web of Science ®Google Scholar
• CDC. Chickenpox [www.cdc.gov]; 2018 Available from: https://www.cdc.gov/chickenpox/hcp/index.html#vaccination-impact. Accessed 218, 2019.
   Google Scholar
• Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA. 2002;287(5):606–611. doi:10.1001/jama.287.5.60611829699
   PubMed Web of Science ®Google Scholar
• Prevention of Varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Available from: https://www.cdc.gov/mmwr/preview/mmwrhtmL/rr5604a1.htm. Accessed 38, 2019.
   Google Scholar
• Banz K, Iseli A, Aebi C, Brunner M, Schmutz AM, Heininger U. Economic evaluation of varicella vaccination in Swiss children and adolescents. Hum Vaccin. 2009;5(12):847–857. doi:10.4161/hv.989819829048
   PubMed Web of Science ®Google Scholar
• Holl K, Sauboin C, Amodio E, Bonanni P, Gabutti G. Coverage, efficacy or dosing interval: which factor predominantly influences the impact of routine childhood vaccination for the prevention of varicella? A model-based study for Italy. BMC Public Health. 2016;16(1):1103. doi:10.1186/s12889-016-3738-x27769206
   PubMed Web of Science ®Google Scholar
• Wutzler P, Bonanni P, Burgess M, Gershon A, Sáfadi MA, Casabona G. Varicella vaccination - the global experience. Expert Rev Vaccines. 2017;16(8):833–843. doi:10.1080/14760584.2017.134366928644696
   PubMed Web of Science ®Google Scholar
• ECDC. Varicella vaccination in the European Union. Available from: https://ecdc.europa.eu/en/varicella. Published 2015 Accessed 38, 2019.
   Google Scholar
• Law-Decree 7 June 2017, N. 73. Disposizioni Urgenti in Materia Di Prevenzione Vaccinale. [Urgent Dispositions regarding Vaccination Prevention]. Italy: GU serie generale n.130 del 7-06-2017 Italian.
   Google Scholar
• Thiry N, Beutels P, Van Damme P, Van Doorslaer E. Economic evaluations of varicella vaccination programmes. Pharmacoeconomics. 2003;21(1):13–38. doi:10.2165/00019053-200321010-00002
   PubMed Web of Science ®Google Scholar
• Brisson M, Racine E, Drolet M.  The Potential Impact of Varicella Vaccination in Low to Middle Income Countries : A Feasibility Modeling Study Report to the SAGE Working Group on Varicella and Herpes Zoster Vaccines. Available from: https://www.who.int/immunization/sage/meetings/2014/april/5_the_potential_impact_varicella_vaccination_low_middle_income_countries_feasibility_modeling.pdf?ua=1. Accessed March 7, 2019.
   Google Scholar
• Edmunds WJ, Brisson M. The effect of vaccination on the epidemiology of varicella Zoster virus. J Infect. 2002;44(4):211–219. doi:10.1053/jinf.2002.098812099726
   PubMed Web of Science ®Google Scholar
• Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect. 2000;125(3):651–669. doi:10.1017/S095026880000471411218215
   PubMed Web of Science ®Google Scholar
• Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet. 2002;360(9334):678–682.12241874
   PubMed Web of Science ®Google Scholar
• Marin M, Meissner HC, Seward JF. Varicella prevention in the United States: a review of successes and challenges. Pediatrics. 2008;122(3):e744–e751. doi:10.1542/peds.2008-056718762511
   PubMed Web of Science ®Google Scholar
• Guris D, Jumaan AO, Mascola L, et al. Changing varicella epidemiology in active surveillance sites—united States, 1995–2005. J Infect Dis. 2008;197(s2):S71–S75.18419413
   PubMed Web of Science ®Google Scholar
• Tanuseputro P, Zagorski B, Chan KJ, Kwong JC. Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program. Vaccine. 2011;29(47):8580–8584. doi:10.1016/j.vaccine.2011.09.02421939721
   PubMed Web of Science ®Google Scholar
• Toyama N, Shiraki K. Universal varicella vaccination increased the incidence of herpes zoster in the child-rearing generation as its short-term effect. J Dermatol Sci. 2018;92(1):89–96. doi:10.1016/j.jdermsci.2018.07.00330041832
   PubMed Web of Science ®Google Scholar
• Gershon AA. Is chickenpox so bad, what do we know about immunity to varicella zoster virus, and what does it tell us about the future? J Infect. 2017;74(Suppl 1):S27–S33. doi:10.1016/j.jinf.2016.12.01628646959
   PubMed Web of Science ®Google Scholar
• Marchetti S, Guzzetta G, Flem E, Mirinaviciute G, Scalia Tomba G, Manfredi P. Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway. Vaccine. 2018;36(8):1116–1125. doi:10.1016/j.vaccine.2018.01.03829366704
   PubMed Web of Science ®Google Scholar
• CDC. CDC′s advisory committee recommends “Shingles” vaccination, press release. Available from: https://www.cdc.gov/media/pressrel/r061026.htm. Published 2006 Accessed 311, 2019.
   Google Scholar
• Lu P-J, O’Halloran A, Williams WW, Harpaz R. National and State-Specific Shingles Vaccination Among Adults Aged ≥60 Years. Am J Prev Med. 2017;52(3):362–372. doi:10.1016/j.amepre.2016.08.03127720342
   PubMed Web of Science ®Google Scholar
• Herpes Zoster (Shingles) Vaccine: Canadian Immunization Guide - Canada.ca. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-8-herpes-zoster-(shingles)-vaccine.html. Accessed 311, 2019.
   Google Scholar
• EMA. Zostavax | European Medicines Agency. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/zostavax. Published 2016 Accessed 311, 2019.
   Google Scholar
• ECDC. ECDC vaccine scheduler. Avaolable from: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=51&SelectedCountryIdByDisease=−1. Accessed 311, 2019.
   Google Scholar
• Robert Koch Institut - Impfungen A-Z - Gürtelrose (Herpes zoster) [Robert Koch Institut - Vaccinations A-Z - Shingles (Herpes Zoster)]. Avalaible from: https://www.rki.de/SharedDocs/FAQ/Herpes_zoster/FAQ-Liste.html?nn=2375548. Accessed 528, 2019 German.
   Google Scholar
• Italian Ministry of Health. Piano Nazionale Prevenzione Vaccinale 192017–2019. [National vaccinal prevention plan 2017-2019]. Available from: http://www.salute.gov.it/portale/documentazione/p6_2_2_1.jsp?lingua=italiano&id=2571. Accessed 523, 2018 Italian.
   Google Scholar
• Bundesministerium für Arbeit Soziales Gesundheit und Konsumentenschutz. Impfplan Österreich 2019, Version 1. [Austrian Vaccination Plan 2019, version 1]. Available from: https://www.sozialministerium.at/site/Gesundheit/Krankheiten_und_Impfen/Impfen/Oesterreichischer_Impfplan_2019. Accessed 3 11, 2018. German.
   Google Scholar
• National Immunisation Program Schedule | Australian Government Department of Health. Available from: https://beta.health.gov.au/health-topics/immunisation/immunisation-throughout-life/national-immunisation-program-schedule. Accessed 311, 2019.
   Google Scholar
• New Zealand Ministry of Health. Immunisation Handbook 2017. Available from: https://www.health.govt.nz/publication/immunisation-handbook-2017. Published 2018 Accessed 311, 2018.
   Google Scholar
• Hoshi S, Kondo M, Okubo I. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan. Vaccine. 2017;35(24):3264–3271. doi:10.1016/j.vaccine.2017.04.04628479176
   PubMed Web of Science ®Google Scholar
• National Institute of Infectious Diseases. 日本の予防接種スケジュール. [Japan vaccination schedule]. Avalaible from: https://www.niid.go.jp/niid/ja/vaccine-j/2525-v-schedule.html. Accessed 528, 2019 Japanese.
   Google Scholar